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Background: Although surgery and anesthesia induce immunesuppression, remains largely unknown whether
various anesthetic techniques have different immunosuppressive effects on cancer patients. Therefore, the aim of
this study was to investigate the influence of total intravenous anesthesia with target-controlled infusion (TIVA-TCI)
and balanced inhalation anesthesia (BAL) on the peri-operative levels of inflammatory cytokines and regulatory T
cells (Tregs) in patients with bladder cancer undergoing surgery.
Methods: Twenty eight consecutive patients with bladder cancer who underwent radical cystectomy were
prospectively randomized into two groups to receive TIVA-TCI (n = 14) or BAL (n = 14). Before the induction of
anesthesia (T0), 6–8 hours (T1) post-surgery, and 5 days post-surgery (T2), Tregs and serum levels of interleukin -1beta
(IL-1β), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin −2 (IL-2), interleukin −6 (IL-6), and
interleukin −10 (IL-10) were measured.
Results: In the peri-operative period all cancer patients showed a marked and significant increase in IL-6. Moreover,
TIVA-TCI patients also showed a higher increase in IFN-γ, whereas in BAL patients Tregs were reduced by approximately
30% during surgery. The incidence of infections, metastases, and death was similar in both groups.
Conclusions: The increase in the Th1 response in the TIVA-TCI group and the reduction in Tregs in the BAL group
seem to balance the immunosuppressive effect induced by IL-6. Therefore TIVA-TCI and BAL can be both used in major
surgery in patients with bladder cancer without worsening the outcome.
Keywords: Total intravenous anesthesia with target-controlled infusion (TIVA-TCI), Balanced inhalation anesthesia (BAL),
Urinary bladder carcinoma, Cytokines, TregsBackground
Increasing evidence supports the role of inflammation in
tumor development, invasion, and metastasis, influen-
cing the host immune response to the tumor [1]. This
has been demonstrated in some tumors, particularly in
bladder carcinoma, which is promoted by chronic in-
flammation and is uniquely sensitive to acute inflamma-
tion [2,3]. In addition, the surgical stress associated with* Correspondence: forastiere@ifo.it
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reproduction in any medium, provided the orgeneral anesthesia causes immune suppression that
accelerates the growth of neoplastic cells and premature
enhanced metastasis [4-6].
Tumor-associated macrophages and T cells modify the
microenvironment and are relevant to cancer progression.
Tumor cell proliferation and invasion are also correlated
with the release of specific cytokines [1,7]. Proinflammatory
cytokines such as interleukin-6 (IL-6), tumor necrosis
factor-alpha (TNF-α), and interleukin -1beta (IL-1β), which
are released from tumor-infiltrating leukocytes, can activate
signal transducers and activators of transcription protein 3
(STAT3), which induces immunosuppression that favorsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suppression and cancer-promoting effects. Two subpopula-
tions of lymphocytes have been described: those with Th1
or Th2 activity [10]. Th1 cells secrete pro-inflammatory
cytokines, namely interferon-gamma (IFN-γ), and favor ac-
tivation of macrophages and the inflammatory response.
Th2 cells, with their pattern of cytokines interleukin-4
(IL-4) and interleukin-10 (IL-10), mediate the production
of antibodies and have anti-inflammatory effects. In many
tumors, such as colorectal cancer, melanoma, and pancrea-
tic cancer, the Th1 response correlates with better progno-
sis [1,11,12]. Th1 cells probably exert a tumor suppressive
effect also in bladder cancer [13]. Furthermore, induction
of the T-helper type 1 immune response is required for ef-
fective bacillus Calmette-Guérin immunotherapy for blad-
der cancer [14].
Recent studies suggest that regulatory T cells (Tregs),
a subpopulation of CD4+ T cells, play a fundamental
role in maintaining immune tolerance [15-17]. Increasing
evidence suggests that infiltrating and circulating Tregs
inhibit antitumor immunity and promote tumor growth
and disease progression, as observed in some clinical
studies [18,19].
Nevertheless, only a few studies have evaluated the im-
munosuppressive effect of different anesthetic techni-
ques in cancer patients undergoing major surgery. No
guidelines for anesthesia procedures for cancer patients
are available even though guidelines for operative proce-
dures have been formulated for different types of cancer
[20]. Previous studies on the role of inhaled and intra-
venous anesthetics in immune suppression showed
contradictory results and appeared to be correlated with
the type of cancer and surgery [20-23]. To our know-
ledge, no study has evaluated the effect of different
anesthetic techniques in patients undergoing surgery for
bladder cancer. Only Wang et al. [24] have assessed an
increase in serum levels of IL-6 in patients undergoing
radical cystectomy with intravenous anesthesia.
Thus, the aim of this study was to investigate the immu-
nomodulatory effects of two established anesthetic techni-
ques, total intravenous anesthesia with target-controlled
infusion (TIVA-TCI) and balanced inhalation anesthesia
(BAL), in patients with bladder cancer undergoing elective
radical cystectomy and urinary bladder reconstruction via
a Paduan ileal bladder, by studying changes in pro- and
anti-inflammatory cytokines and Tregs.Methods
Patient population
This study was approved by the Ethics Committee of
the National Cancer Institute Regina Elena, Rome (Prot.
CE/94/12), and written informed patient consent was
obtained from all participants.Between February 2010 and March 2011, 28 consecu-
tive Caucasian patients with primary urothelial bladder
cancer undergoing elective radical cystectomy were
enrolled.
Patients with bladder cancer (22 males and 6 females,
mean age 62.04 ± 8.63 years) were randomly assigned to
receive either TIVA-TCI (n = 14) or BAL (n = 14).
Randomization was based on a global assessment of
anesthetic risk (ASA 1–2 vs. 3). A random code deter-
mined the anesthetic protocol. The surgeons, research
assistants, medical staff, and nursing staff were blinded
to the group assignment.
Exclusion criteria
Exclusion criteria included: ASA >3, metabolic equivalent
task <4, obesity, hemoglobin concentration <10 g/dl,
endocrinologic, immunologic, and chronic infective dis-
eases, diabetes, cortisone and immunosuppressive therapy,
beta-blockers or angiotensin-converting enzyme inhibitor
therapy, alcohol abuse, chronic liver disease, and chronic
pain. None of the patients had received previous neo-
adjuvant treatments (chemo, hormone, and radiotherapy).
Anesthetic protocol
Thirty minutes before induction of anesthesia, all patients
received 10 mg intramuscular ketoralac trometamina
(Toradol™, Recordati, Milano, Italy) or 100 mg tramadolo
cloridrato (Contramal™, AIC Formenti, Milano, Italy),
100 mg ranitidine (Ranidil™, Menarini, Firenze, Italy), and
0.5 mg atropine (Industria Farmaceutica Galenica Senese,
Siena, Italy). Prior to starting anesthesia, a FloTrac pres-
sure transducer was connected (Edwards Lifesciences,
Irvine, CA) to the Vigileo system (Edwards Lifesciences,
v.1.07) and inserted into a radial artery to monitor dy-
namic variables. In addition, central venous pressure and
central venous oxygen saturation (ScvO2) were monitored
from the right internal jugular vein.
Before starting surgery, patients in the TIVA-TCI group
received a combination of propofol (Diprivan™, ASTRA-
Zeneca, Milano, Italy) and remifentanyl (Ultiva™,
GlaxoSmith-Kline AB, Verona, Italy). Propofol was admi-
nistered with TCI though infusion pumps (Alaris PK
CardinalHealth, Rolle, Switzerland). At induction, the tar-
get plasma dose was 4 mg/m and was decreased to 3 μg/ml
during the operation. Remifentanil was administered as a
continuous intravenous infusion. At induction, the dose
was 0.25 μg kg-1 min-1, and it was lowered to 0.15 μg
kg-1 min-1 during surgery. This combination was modified
by 0.05-μg kg-1 min-1 steps according to analgesic needs
and hemodynamic parameters.
In the BAL group, patients received inhalation anesthesia
with sevoflurane/O2/air (Sevorane
™, Abbott, Latina, Italy)
throughout the entire surgery. Before induction of
anesthesia, 1–2 μg/kg fentanyl (Fentanest™, Pftzer, Latina,
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0.1-0.2 mg/kg midazolam (Hameln pharmaceuticals
Gmbh, Hameln, Germany), and the inhalation anesthesia
was comprised of a mixture of sevoflurane/O2/air. For
maintenance, the end-tidal sevoflurane concentration was
kept at 1.4-2.8 vol %.
In both groups, 0.1-0.5 mg/kg cisatracurium besylate
(Nimbex™, Glaxo Smith Kline) was given to facilitate oro-
tracheal intubation, followed by the continuous application
of 0.06-0.12 mg kg-1 h-1 cisatracurium via infusion pumps.
The lungs were mechanically ventilated in a volume-
control mode with settings aimed at achieving normocap-
nia, reaching a tidal volume up to 8–10 ml/kg and a re-
spiratory frequency of 10–12 breaths/min. Mechanical
ventilation was initiated with a mixture of 50% O2 and 50%
air, and the inspired oxygen concentration was 40% during
surgery. All patients were kept supine during the operation.
No patient received inotropes, vasopressors or methoclo-
pramide during or after surgery.
Monitoring included evaluation of cardiac hemodynamic
parameters (electrocardiogram, heart rate, invasive blood
pressure, systolic, diastolic, mean blood pressure [MAP],
central venous pressure, stroke volume variation, cardiac
index); tissue perfusion markers (ScvO2, O2 delivery index,
arterial lactates, base excess, diuresis), respiratory para-
meters (pulse oximetry, end-tidal CO2, airway pressure,
end-tidal sevoflurane), esophageal temperature, and blood
glucose. The type of fluids (colloid and crystalloid)
and the total volume were administered according to
the goals optimized for a Cardiac Index >2.5 L/min/m2,
MAP >90-105 mmHg, and Oxygen Delivery Index
>600 ml/min/m2. Furthermore, the ScvO2 value was main-
tained at ≥70%. Patients received 1 packed red cell unit for
each 1 g/dl of hemoglobin when its value was <8 g/dl.
After surgery, the residual neuromuscular blockade
was reversed with a mixture of atropine and neostigmine
(Intrastigmina™, Lusofarmaco, Milano, Italy) only if
deemed clinically necessary. Anesthetic agents were
switched off, and 100% O2 was given with 8 l/min fresh
gas flow for 1 min. Supplemental oxygen was not given
postoperatively.
Hypothermic prevention during anesthesia was achieved
by warm venous infusion (warmed serum), and a thermal
blanket was applied to cover the upper part of the body.
In addition, a warming forced-air blanket was used post-
surgery (Equator Covective Warming™, Smith Medical
Italia, Milano, Italy).
After tracheal extubation, all patients received an intra-
venous bolus of 2 mg morphine (Recordati). A patient-
controlled analgesia device (Deltec™ , Smiths Medical
ASD, St Paul, MN) was then connected to an intravenous
infusion device and was set to deliver 1 mg morphine with
a 7-min lockout time. Patient-controlled analgesia was
maintained until daily morphine consumption was <10 mg.In addition, patients received 20 mg ketoralac for 3 days or
100 mg tramadolo cloridrate for 1 day.
Peri-operative protocol
Before the induction of anesthesia (T0), 6–8 hours post-
surgery (T1), and 5 days post-surgery (T2), blood sam-
ples were drawn to determine immunologic parameters,
including Tregs and the serum concentration of IL-1β,
IFN-γ, TNF-α, IL-2, IL-6, and IL-10.
The following clinical parameters were evaluated:
(a) histological type and pathological tumor-node-
metastasis stage, (b) quantity and type of liquids adminis-
tered, (c) blood loss, (d) transfusion of allogenic blood and/
or autotransfusion, (e) pre and post-operative complications
such as hypertension, hyperglycemia, hypothermia, and
pain (evaluated by a 6-point verbal rating scale: 0: no pain
to 5: most severe pain imaginable), (g) post-operative infec-
tion rate.
Furthermore, follow-up was performed to assess the
disease-free interval, metastasis, and survival of each
patient.
Serological parameters
The serum levels of different cytokines were measured
with enzyme immunoassays (IL-2 and IL-10, Boster
Biological Technology, CA, USA) or multiparametric
assays based on chemiluminescent detection of a cyto-
kine array. The latter allows simultaneous detection of
multiple molecules (IL-6, IFN-γ, TNF-α, IL-1β; Human
cytokine array and SignaturePLUS™ CCD Imaging &
Analysis System, Aushon Biosystem, MA, USA).
Evaluation of tregs
Peripheral blood mononuclear cells were isolated by gra-
dient centrifugation, and Tregs were identified by the ex-
pression of CD4 and CD25 on the cell membrane and
by FoxP3 intracellular staining using flow cytometry as
previously described [25]. (Both the detecting antibodies
and the FacsCalibur flow cytometer were from BD Bios-
ciences, San Jose, CA).
Statistical analysis
Data were analyzed with Statistical Package for the
Social Sciences (SPSS) 14.0 software. Continuous and
categorical variables were expressed as the mean ±
standard deviation or standard error and as frequency
values and proportions, respectively. Pearson’s chi-square
test was used to assess possible differences in dichoto-
mous variables between the various groups examined. The
means of normally distributed data were compared with
the Student’s t-test.. In the other cases, the groups were
compared with the Mann-Whitney’s U test. P values of
the tests were adjusted using the Bonferroni method.
Paired samples were analyzed by t-test and Wilcoxon
Table 2 Perioperative clinical data of patients with
bladder cancer who underwent radical cystectomy with
TIVA-TCI or BAL anesthesia
TIVA BAL P TIVA
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Results
Clinical characteristics of the patients
The clinical characteristics of the patients enrolled in
the study are reported in Table 1. No significant differ-
ences were observed regarding age or gender between
TIVA-TCI and BAL cancer patients. Eighteen out of 28
patients who underwent surgery (64.3%) had an ASA I-II
(9 in each group), whereas 10 (35.7%) had an ASA III. The
mean duration of anesthesia was 3.27 ± 0.48 h, with
no differences between the TIVA-TCI and BAL groupsTable 1 Clinical characteristics of patients with bladder











Age (yrs) 62.04 ± 8.63 63.2 ± 6.8 61.2 ± 10.8 0.57
Sex , n (%)
males 23 (82.1%) 12 (85.7%) 11 (78.6%) 0.62






28 (100%) 14 (100%) 14 (100%) 1.00
pT, n (%)
1-2 11 (39.3%) 6 (42.9%) 5 (35.7%) 0.70
3 17 (60.7%) 8 (57.1%) 9 (64.3%)
pN, n (%)
0 22 (78.6%) 12 (85.7%) 10 (71.4%) 0.34
1 2 (7.1%) 0 2 (14.3%)
2 4 (14.3%) 2 (14.3%) 2 (14.3%)
ASA, n (%):
I-II 18 (64.3%) 9 (64.3%) 9 (64.3%) 1.00
III 10 (35.7%) 5 (35.7%) 5 (35.7%)
Weight (BMI ) 25.8 ± 4.2 27.1 ± 5.9 25.1 ± 3.0 0.55
Time of surgery (h) 3.12 ± 0.59 3.08 ± 0.58 3.17 ± 0.56 0.27
Time of
anaesthesia (h)











4 (14.3%) 1 (7.1%) 3 (21.4%) 0.28
Death from
cancer, n (%)
5 (17.9%) 1 (7.1%) 4 (28.6%) 0.14
Death from any
cause, n (%)
7 (25.0%) 2 (14.3%) 5 (35.7%) 0.19
Values are expressed in absolute values or mean ± SD.(p = 0.42). All patients showed a high grade urothelial car-
cinoma (G3). No significant differences between the two
groups were observed regarding tumor size, invasiveness
(pT), lymph node involvement (pN), body mass index,
time of surgery and hospitalization.
During surgery, decreases in hematocrit and hemoglobin
concentration were observed in both groups, but intra-
operative blood loss was similar (Table 2). Transfusion of( n. 14) (n. 14) vs. BAL
HB (g/dl)
Pre-anaesthesia 13.51 ±1.80 14.42 ± 1.33 0.14
Intraoperative 9.82 ±1.63 10.43 ± 1.82 0.47
5 days post-surgery 9.63 ±1.24 9.70 ± 1.35 0.86
HCT (%)
Pre-anaesthesia 39.53 ± 5.23 42.55 ± 4.47 0.14
Intraoperative 28.2 ±5.12 30.33 ± 5.41 0.52
5 days post-surgery 29.16 ±4.85 28.32 ± 3.80 0.65
Blood loss (ml) 1596 ± 365 1539 ± 418 0.70
Total amount of
crystalloid received (ml)
3250 ± 1513 2875 ± 772 0.49
Total amount of colloid
received (ml)
350 ± 250 300 ± 250 0.61
Blood transfusion (n) 1.15 ± 1.64 1.22 ± 1.71 0.96
Intraoperative
autotransfusion (n)
0.47 ± 0.71 0.33 ± 0.62 0.82
Intraoperative body
temperature (°C)
36.14 ± 0.22 36.24 ± 0.26 0.93
Intraoperative blood
glucose (mg/dl)
120.04 ± 21.38 116.63 ± 23.61 0.72
Intraoperative MAP
(mmHg)
103.66 ± 12.82 106.41 ± 12.13 0.60
Intraoperative CVP
(cm H2O)
10.32 ± 1.23 10.14 ± 1.33 0.75
Intraoperative SpO2 (%) 97.60 ± 0.92 96.61 ± 2.82 0.30
Arterial lactate level
(mmol/l)
1 h post-surgery 0.82 ± 0.22 0.61 ± 0.34 0.82
6 h post-surgery 1.77 ± 0.32 1.87 ± 0.25 0.83
5 days post-surgery 1.32 ± 0.35 1.27 ± 0.22 0.91
Intraoperative BE (mmol/l) 0.32 ± 0.51 0.43 ± 0.38 0.53
Intraoperative PaO2
(mmHg)
222.21 ± 10.23 215.11 ± 23.11 0.73
Pain (Verbal Rating Scale)
1 h post-surgery 1.32 ± 0.62 1.22 ± 0.81 0.59
6 h post-surgery 1.14 ± 0.44 1.07 ± 0.51 0.54
5 days post-surgery 0.73 ± 0.56 0.82 ± 0.64 0.46
Values are presented as mean ± SD.
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and 6 patients, respectively (5 and 3 in the TIVA-TCI
group and 6 and 3 in the BAL group, respectively), with no
significant differences in the number of transfusions be-
tween groups. Also, the volume of electrolyte solution
administered during anesthesia was similar in the TIVA-
TCI and BAL groups (Table 2). Similarly, no statistical
differences were observed between groups regarding
hemodynamic and respiratory parameters, tissue perfusion
markers, temperature, or glucose levels (Table 2).
None of the patients experienced adverse events during
their postoperative course such as pulmonary infections
requiring antibiotic treatment, systemic inflammatory re-
sponse syndrome, sepsis, acute respiratory distress syn-
drome, or surgical revision.
Metastases after surgery were observed in only 4 out of
28 cancer patients (14.3%): one in the TIVA-TCI group
and 3 in the BAL group (p = 0.28) (Table 1). No significant
differences were observed in the incidence of death from
any cause or tumors between the TIVA-TCI and BAL
groups, even though the number of patients who had died
was higher in the BAL group (4 in BAL vs. 1 in TIVA-TCI,
p = 0.14) (Table 1).
Changes in concentrations of inflammatory cytokines
TIVA-TCI patients showed a marked and significant in-
crease in IL-6 at T1 (6–8 hours post-surgery), reaching a
value of 132.6 ± 37.9 pg/ml compared to the value of 5.3 ±
4.4 pg/ml measured before surgery (T0; p = 0.005), anTable 3 Changes of immunologic parameters before inductio
5 days post-surgery (T2) in patients who underwent TIVA-TCI
T0
TIVA-TCI BAL TIVA-
IL-1β (pg/ml) 0.58 ± 0.53 0.59 ± 0.53 0.57 ±
IFN-γ (pg/ml) 0.55 ± 0.48 0.57 ± 0.41 0.53 ±
TNF-α (pg/ml) 0.94 ± 0.64 0.76 ± 0.74 0.72 ±
IL-2 (pg/ml) 20.99 ± 4.22 21.33 ± 5.10 20.24 ±
IL-6 (pg/ml) 5.35 ± 4.37 (a,b) 4.28 ± 3.27 (e,f) 132.59 ± 3
IL-10 (pg/ml) 1.50 ± 0.21 1.48 ± 0.15 1.46 ±
Leucocytes (%) 7.79 ± 3.22 9.30 ± 4.73 11.98 ±
Lymphocytes (%) 16.76 ± 11.23 (c,d) 12.94 ± 12.33 (l) 6.02 ± 5
Tregs (%) 3.01 ± 1.16 3.34 ± 1.75 (n,o) 2.69 ±
Neutrophils (%) 48.30 ± 30.42 54.11 ± 22.27 67.56 ±
Monocytes (%) 5.34 ± 4.40 5.64 ± 3.36 4.58 ±
Eosinophils (%) 1.73 ± 1.26 4.98 ± 4.46 (g) 1.17 ±
Basophils (%)† 1.30 ± 2.45 0.48 ± 0.27 (i) 0.22 ±
Values are presented as mean ± SD.
Statistical analysis:
TIVA-TCI : (a) T0 vs T1 p = 0.005, (b)T0 vs T2 p = 0.005; (c) T0 vs T1 p = 0.01, (d) T0 v
BAL : (e) T0 vs T1 p = 0.005, (f) T0 vs T2 p = 0.005; (g) T0 vs T1 p = 0.005, (h) T1 vs T
(n) T0 vs T1 p = 0-02, (o)T0 vs T2 p = 0.03.
TIVA-TCI vs. BAL : (p) p = 0.01 ; (q) p = 0.04.increase of about 50-fold (Table 3, Figure 1). These values
were reduced 5 days post-surgery (T2), but remained
about 10-fold higher than baseline values (p = 0.005). Even
in the BAL group, we observed a similar increase at T1
(132.4 ± 53.9 pg/ml vs. 4.2 ± 3.3 pg/ml, p = 0.005) that was
followed by a reduction at T2 that remained about 10
times higher than baseline values (p = 0.005) (Table 3). No
significant differences were found between TIVA-TCI and
BAL groups in the levels of IL-6 just before surgery or
peri-operatively.
The TIVA-TCI group showed a significant increase in
TNF-α levels between T2 and T0 compared to the BAL
group (2.34 vs. 1.29 times, respectively, p = 0.001). At
T1, the levels of TNF-α were not significantly different,
possibly due to the high variability observed. The values
of IL-2 remained constant during the three measure-
ments (Figure 1).
Th1 pro-inflammatory activities were evaluated by mea-
suring plasma levels of IFN-γ. Although we observed only
slight changes between T0 and T1, the differences became
significant at T2 when there was an increase by 1.5-fold
compared to T0. The increase in IFN-γ observed at T2 was
significantly different in patients undergoing TIVA-TCI
compared to BAL (Figure 1). In fact, IFN-γ levels showed a
mean increase of 2.26-fold at T2 in the TIVA-TCI group
and only 1.03-fold in the BAL group (p = 0.002).
There were no significant changes in Th2 activity just
before surgery and peri-operatively, as assessed by IL-10
levels (Figure 1).n of anaesthesia (T0), 6–8 hours post-surgery (T1) and
and BAL anesthesia
T1 T2
TCI BAL TIVA-TCI BAL
0.48 0.62 ± 0.52 0.60 ± 0.53 0.69 ± 0.50
0.42 0.58 ± 0.51 1.07 ± 0.48 (p) 0.58 ± 0.58 (p)
0.45 0.98 ± 1.01 1.88 ± 1.18 (q) 1.28 ± 1.10 (q)
3.02 23.38 ± 6.22 18.46 ± 2.30 21.21 ± 6.70
7.91 (a) 132.81 ± 54.23 (e) 53.60 ± 111.20 (b) 40.76 ± 50.82 (f)
0.31 1.50 ± 0.16 1.55 ± 0.29 1.51 ± 0.21
3.99 13.09 ± 4.65 9.54 ± 2.25 9.14 ± 3.57
.45 (c) 7.97 ± 6.36 (l,m) 8.45 ± 8.66 (d) 11.80 ± 9.19 (m)
0.97 2.45 ± 2.22 (n) 2.79 ± 1.32 2.41 ± 1.27 (o)
31.16 62.70 ± 30.54 58.50 ± 28.09 63.30 ± 20.23
3.67 4.57 ± 3.74 6.61 ± 4.14 6.65 ± 3.82
3.05 0.80 ± 1.38 (g,h) 2.23 ± 1.63 4.65 ± 2.87 (h)
0.16 0.20 ± 0.27 (i) 0.60 ± 0.48 0.37 ± 0.24
s T2 p = 0.05.
































Figure 1 Changes in cytokine levels between T0 (before the
induction of anesthesia) and T1 (6–8 hours post-surgery) and
between T0 and T2 (5 days post-surgery) in all cases, in TIVA-TCI,
and BAL. TIVA-TCI and BAL patients showed a marked and
significant increase in IL-6 at T1 compared to values prior to surgery
(T0) (p = 0.005), with an increase of about 50 times. These values
were reduced at T2, but remained about 10 times higher than
baseline values (p = 0.005). There were no significant differences
between the TIVA-TCI and BAL groups. The TIVA-TCI group showed
a significant increase in TNF-α levels between T2 and T0 compared
to the BAL group (2.34 vs. 1.29 times, p = 0.001). At T1, differences
were not statistically significant due to the high variability observed.
Similarly, the increase in IFN-γ observed at T2 was significantly
different in patients undergoing TIVA-TCI anesthesia compared to
BAL. IFN-γ levels showed an increase of 2.26 times at T2 compared
to T0 in the TIVA-TCI group and only 1.03 times in the BAL group
(p = 0.002). The values of other cytokines remained constant during
the three measurements in both groups.
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Some changes in blood cells were observed during
anesthesia and surgery. Both TIVA-TCI and BAL
patients showed a significant reduction in lymphocytes
at T1 (p = 0.01 and p = 0.04, respectively) that slightly
increased at T2 (Table 3).
Interestingly, the BAL group showed a significant re-
duction in Tregs (p = 0.02) at T1, which was maintained
at T2 (T0 vs. T2, p = 0.03) (Table 3). In contrast, TIVA-TCI patients showed no changes in Treg levels just be-
fore surgery and postoperatively (Table 3).
The reduction in circulating lymphocytes and Tregs at
T1 was associated with a significant reduction in eosino-
phils (p = 0.005) and basophils (p = 0.01) in the BAL
group, and these values returned to baseline values at
T2 (Table 3). Because no other changes in leukocytes or
monocytes were demonstrated, the reported modifica-
tions of lymphocytes we observed appear to be inde-
pendent of the hemodilution.
Discussion
The results of our study show that all patients with bladder
cancer showed a notable increase in IL-6 peri-operatively.
In patients undergoing TIVA-TCI anesthesia, the increase
in IL-6 was also associated with a significant increase in the
pro-inflammatory Th1 cytokine IFN-γ. In contrast, in BAL
patients Tregs were reduced by about 30% during surgery
and remained low up to 5 days after surgery (Table 3,
Figure 1).
Our study suggests that the marked increase in serum
IL-6 observed in the early post-operative period is not
related to the type of anesthesia and pain, but appears to
be mainly related to surgical stress as demonstrated by
previous studies [22,26,27]. It has been hypothesized that
release of IL-6 during surgical stress determines the re-
lease of catecholamine and glucocorticoids, which induce
immune suppression [4,28]. The immunosuppressive ef-
fect was also observed in our cases by the reduction in cir-
culating lymphocytes at T1, which persisted at T2 and was
independent of the type of anesthetic used.
Previous studies regarding the immune suppressive ef-
fect of inhaled and intravenous anesthetics have been
contradictory [20-23]. Our results are in agreement with
findings of a recent study by Kvarnsrtom et al. [26], who
observed a similar increase in IL-6 levels in the peri-
operative period in cancer patients undergoing major ab-
dominal surgery who were randomized to receive either
propofol-remifentanil or sevoflurane-fentanyl. An in-
crease in IL-6 was also observed in patients without can-
cer undergoing anesthesia with sevoflurane [29,30].
Conversely, others studies have reported low serum
levels of IL-6 in patients given TIVA anesthesia in com-
parison to inhaled anesthetics [31] and in some experi-
mental studies after administration of propofol [32].
Other studies reported a suppression of the production
of IL-6 by sevoflurane [33,34].
It is currently unclear whether these differences are
due to the type of cancer or surgery or depend on other
still unrecognized causes. This is the first study to eva-
luate changes in the levels of cytokines induced by two
different anesthetic techniques in patients with bladder
cancer undergoing cystectomy. A few earlier studies had
shown a greater increase in IL-6 in patients undergoing
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went laparoscopy [24,35]. IL-6 is a multifunctional cyto-
kine that supports cancer cell proliferation and inhibits
apoptosis through activation of STAT3 [36,37]. The role
of IL-6 in human cancer is reinforced by the observation
of elevated serum levels of IL-6 and soluble IL-6 recep-
tor in patients with bone metastasis and a poor clinical
outcome [38]. Additionally, IL-6 acts as an angiogenic
factor [38]. IL-6 and STAT are activated by modifications
in MAP and O2 saturation [39]. The fact that in our
study MAP and O2 saturation were constant in both
techniques confirms the hypothesis that the increase in
IL-6 is specifically related to surgical manipulation and
anesthesia and is independent of the type of anesthetic
drugs used. In the BAL group, at the end of surgery (T1)
(Table 3), and in the TIVA-TCI group, after 5 days (T2),
an increase in TNF-α levels was also observed (Table 3).
It is important to note that increased TNF-α expression
has been reported in recurrent, larger bladder tumors as
well as in tumors that show progression in grade and
stage [40].
The immunosuppressive effect of surgery produces a
reduction in progression-free survival and an increase in
developing infections in the peri-operative period [23].
Because no patients in our study showed infections in
the postoperative week with either anesthetic technique,
we hypothesize that there was an immunomodulatory ef-
fect that antagonized the immunosuppression and was
likely correlated with the increase in IL-6 levels during
surgery. In addition, non-statistically significant differ-
ences in progression-free survival, overall survival, and
occurrence of metastases were observed between the
TIVA-TCI and BAL groups. This immunomodulatory ef-
fect occurred with both anesthetic techniques albeit in
different ways.
A significant increase in the Th1 response was found in
patients undergoing TIVA-TCI anesthesia. This finding was
illustrated by the fact that 5 days after surgery (T2), the
levels of IFN-γ increased 2.26-fold compared to pre-surgery
values (Figure 1). Because IL-10 levels remained constant in
both groups, the Th2 response did not appear to be altered
by either anesthetic procedure.
Th1 cells probably exert a tumor suppressive effect in
bladder cancer [13]. In fact, in bladder tumor patients, a
marked polarization exists towards the expression of Th2-
type cytokines, whereas Th1 remains suppressed. Th1 cyto-
kines play an important role in bacillus Calmette-Guérin
(BCG)-induced macrophage cytotoxicity, and the combi-
nation of BCG with select Th1-stimulating cytokines may
enhance the effect of BCG in the treatment of bladder can-
cer patients [41].
In patients undergoing BAL anesthesia, a significant
reduction in Treg levels of 30% was observed in the
early peri-operative period (T1) (p = 0.03; Table 3) andremained constant up to T2, showing values similar to
those measured in healthy controls. This is the first
study to evaluate the effect on circulating levels of Tregs
due to various types of anesthesia. Earlier evidence sug-
gested that Tregs accumulate in tumors and in the per-
ipheral blood of patients with cancer and through
suppression of the anti-tumor immune response these
cells promote tumor growth and disease progression in
a variety of human malignancies, including bladder can-
cer [18,19,42]. The role of Tregs in metastasis is just be-
ginning to emerge, and circulating Tregs are associated
with poor prognosis in some human cancers [43]. In
vivo expansion of Tregs is mediated by glucocorticoid-
induced tumor necrosis factor receptor family-related
(GITR) proteins [44]. Interestingly, Tregs detected in
tumor tissues express high levels of GITR molecules.
Depletion of Tregs by anti-GITR mAb represents a
novel mechanism for cancer immunotherapy [45].
Therefore, the reduction in Tregs we observed in the
BAL group appears particularly remarkable in patients
with bladder cancer, a type of neoplasm that is respon-
sive to immunotherapy.Conclusions
The increase in the Th1 response observed in the TIVA-
TCI group and the reduction in Tregs observed in BAL
patients seem to balance the putative immunosuppres-
sive effect induced by IL-6 and supports the hypothesis
that TIVA-TCI and BAL techniques can be both used
during major surgery in patients with bladder cancer
without worsening the outcome.
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